Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System IV - SPIRIT IV: 2-Year Follow-Up


The SPIRIT I, II, and III trials have demonstrated the safety and efficacy of the everolimus-eluting stent (EES) for the treatment of coronary artery disease (CAD). The current trial sought to compare clinical endpoints between the EES and paclitaxel-eluting stent (PES), Taxus Express.